Open Access

Amyloid precursor protein has clinical and prognostic significance in AML1‑ETO‑positive acute myeloid leukemia

  • Authors:
    • Guopan Yu
    • Changxin Yin
    • Ling Jiang
    • Dan Xu
    • Zhongxin Zheng
    • Zhixiang Wang
    • Chunli Wang
    • Hongsheng Zhou
    • Xuejie Jiang
    • Qifa Liu
    • Fanyi Meng
  • View Affiliations

  • Published online on: November 13, 2017     https://doi.org/10.3892/ol.2017.7396
  • Pages:917-925
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Amyloid precursor protein (APP) has been reported to be highly expressed in acute myeloid leukemia (AML)1‑eight‑twenty one (ETO)‑positive AML. In the present study, the clinical and prognostic significance of APP expression was assessed in 65 patients with AML1‑ETO‑positive AML using reverse transcription‑quantitative polymerase chain reaction. The patients were divided into an APP‑high expression (APP‑H) group (n=32) and an APP‑low expression (APP‑L) group (n=33) according to the cut‑off value of APP relative expression, which was calculated by receiver operating characteristic curve analysis. It was observed that C‑KIT mutations (14/32 vs. 3/33, P=0.009), white blood cell count (median, 23.2x109 vs. 12.4x109 cells/l; P=0.011) and bone marrow cellularity (median, 91.0 vs. 84.0%; P=0.039) and incidence of extramedullary leukemia (11/32 vs. 3/33, P=0.013) were all significantly increased in the APP‑H group compared with the APP‑L group. Furthermore, significantly lower rate of cumulative two‑cycle complete remission (83.9 vs. 100%, P=0.016), major molecular remission following two courses of consolidation (34.5 vs. 71.4%, P=0.005), and poorer relapse‑free survival (RFS) (33.5±5.2% vs. 76.3±6.9%, P<0.001) and overall survival (OS) (44.5±7.0% vs. 81.9±5.8%, P=0.002) were associated with APP overexpression. Multivariate analysis revealed that APP overexpression was a significant adverse factor affecting both RFS and OS. Taken together, these data suggest that APP may be correlated with C‑KIT mutations and involved in leukemia cell proliferation, and its overexpression has an adverse effect on the prognosis in AML1‑ETO‑positive AML.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yu, G., Yin, C., Jiang, L., Xu, D., Zheng, Z., Wang, Z. ... Meng, F. (2018). Amyloid precursor protein has clinical and prognostic significance in AML1‑ETO‑positive acute myeloid leukemia. Oncology Letters, 15, 917-925. https://doi.org/10.3892/ol.2017.7396
MLA
Yu, G., Yin, C., Jiang, L., Xu, D., Zheng, Z., Wang, Z., Wang, C., Zhou, H., Jiang, X., Liu, Q., Meng, F."Amyloid precursor protein has clinical and prognostic significance in AML1‑ETO‑positive acute myeloid leukemia". Oncology Letters 15.1 (2018): 917-925.
Chicago
Yu, G., Yin, C., Jiang, L., Xu, D., Zheng, Z., Wang, Z., Wang, C., Zhou, H., Jiang, X., Liu, Q., Meng, F."Amyloid precursor protein has clinical and prognostic significance in AML1‑ETO‑positive acute myeloid leukemia". Oncology Letters 15, no. 1 (2018): 917-925. https://doi.org/10.3892/ol.2017.7396